ArticleAlzheimer's & dementia (New York, N. Y.)2018
Alzheimer's disease Archimedes condition-event simulator: Development and validation.
Article in Alzheimer's & dementia (New York, N. Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- A systematic review of whole disease models for informing healthcare resource allocation decisions.PloS one · 2023Pooled it
- Assessing technologies in dementia care: A conceptual health-economic model.Journal of Alzheimer's disease : JAD · 2026Article
- Informal care for people with dementia in Europe.The journal of prevention of Alzheimer's disease · 2025Article
- Predicting the Societal Value of Lecanemab in Early Alzheimer's Disease in Japan: A Patient-Level Simulation.Neurology and therapy · 2023Article
- Estimated Societal Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.Neurology and therapy · 2023Article
- A Path to Improved Alzheimer's Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer's Disease from the CLARITY AD Trial.Neurology and therapy · 2023Article
- Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer's Disease.Neurology and therapy · 2022Article
- The Potential Economic Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.Neurology and therapy · 2022Article
- Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.Neurology and therapy · 2022Article
- Using dynamic microsimulation to project cognitive function in the elderly population.PloS one · 2022Article
- Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease.Neurology and therapy · 2021Article
- Evaluation of the Cost-effectiveness of Drug Treatment for Alzheimer Disease in a Simulation Model That Includes Caregiver and Societal Factors.JAMA network open · 2021Article
- Heterogeneity in Reports of Dementia Disease Duration and Severity: A Review of the Literature.Journal of Alzheimer's disease : JAD · 2021Review
- Economic evaluation of supplementing the diet with Souvenaid in patients with prodromal Alzheimer's disease.Alzheimer's research & therapy · 2020Article
- Worth their weight in gray matter? A narrative review of cost-effectiveness analyses of monoclonal antibodies for Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
introductionSeveral advances have been made in Alzheimer's Disease (AD) modeling, however, there remains a need for a simulator that represents the full scope of disease progression and can be used to study new disease-modifying treatments for early-stage and even prodromal AD.
methodsWe developed AD Archimedes condition-event simulator, a patient-level simulator with a focus on simulating the effects of early interventions through changes in biomarkers of AD. The simulator incorporates interconnected predictive equations derived from longitudinal data sets.
resultsThe results of external validations on AD Archimedes condition-event simulator showed that it provides reasonable estimates once compared to literature results on transition to dementia AD, institutionalization, and mortality. A case study comparing a disease-modifying treatment and a symptomatic treatment also showcases the benefits of early treatment. DISCUSSION: The AD Archimedes condition-event simulator is designed to perform economic evaluation on various interventions through close tracking of disease progression and the related clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.